The present exploratory and descriptive retrospective analysis assessed the quality of life (QoL) of CRYSTAL study patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC). Our data suggest that adding cetuximab to first-line FOLFIRI (5-fluorouracil, leucovorin, irinotecan) improved progression-free survival, overall survival, and objective response rate without negatively affecting QoL in CRYSTAL study patients with RAS wt mCRC. Background: Adding cetuximab to FOLFIRI (5-fluorouracil, leucovorin, irinotecan) significantly improved progressionfree survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with KRAS or RAS (KRAS/ NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC) in the first-line CRYSTAL study. The present exploratory and descriptive retrospective analysis assessed the quality of life (QoL) of CRYSTAL study patients with RAS wt mCRC-the labeled indication for cetuximab in many countries. Patients and Methods: Patient QoL was investigated using the European Organisation for Research and Treatment of Cancer QoL questionnaire core-30 (EORTC QLQ-C30). QoL assessments were performed at baseline, after every 8 weeks of treatment, and at the final tumor assessment. RAS wt patients were considered evaluable for QoL if they had provided ! 1 evaluable EORTC QLQ-C30. Results: Of the 367 patients with RAS wt tumors, 351 were evaluable for QoL. Global health status (GHS)/QoL and the time to worsening of Eastern Cooperative Oncology Group performance status were similar between the treatment groups. However, the analysis was complicated by a large decrease in the number of evaluable patients in the FOLFIRI arm between weeks 32 and 40. The individual dimensions of interest in mCRC (eg, social functioning, fatigue, nausea/vomiting, pain, appetite loss, constipation, diarrhea, and functional difficulties) were also similar between the treatment arms. Changes in GHS/QoL and social functioning from baseline to week 8 were similar, irrespective of whether patients experienced early skin reactions. Conclusion: The findings of the present descriptive retrospective analysis suggest that adding cetuximab to first-line FOLFIRI improves PFS, OS, and ORR without negatively affecting the QoL of CRYSTAL study patients with RAS wt mCRC.
Introduction
The addition of the anti-epidermal growth factor receptor monoclonal antibody cetuximab to infusion FOLFIRI (5-fluorouracil, leucovorin, irinotecan) significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in the first-line treatment of patients with KRAS wild type (wt) metastatic colorectal cancer (mCRC) in the randomized phase III CRYSTAL trial.
Previous studies have suggested that patient quality of life (QoL) at baseline might be predictive of survival in various tumor types, including mCRC. [3] [4] [5] [6] [7] Moreover, adding cetuximab to irinotecan or best supportive care has previously been reported to improve QoL in several later-line clinical trials involving patients with mCRC. [8] [9] [10] In the CO.17 study, QoL gains were significantly associated with achievement of a response to therapy or disease control. 9 Remaining unaddressed by these studies, however, was the potential influence of cetuximab on patient QoL when administered as first-line therapy for mCRC. We know from the CRYSTAL study that cetuximab confers a significant gain in survival with a predictable and manageable adverse event (AE) profile when added to first-line FOLFIRI. To undertake a more holistic approach to treatment planning, we sought to ascertain whether these survival gains were at the expense of patient QoL. Therefore, of interest were our subsequent findings that adding cetuximab to FOLFIRI in the KRAS wt population of the CRYSTAL trial improved PFS, OS, and ORR without negatively affecting global health status (GHS)/QoL.
11 Additionally, we have previously reported that toxicity, including cetuximabattributable skin reactions, did not markedly influence the QoL of patients with KRAS wt mCRC treated with cetuximab plus FOL-FIRI in the CRYSTAL study. 12 Further retrospective analysis of the CRYSTAL study data has demonstrated that expanded RAS testing (KRAS/NRAS, exons 2-4) can identify a subgroup of patients with fully RAS wt tumors who are likely to benefit most from the addition of cetuximab to FOLFIRI. 13 However, GHS/QoL has not been previously assessed in the RAS wt population of the CRYSTAL study. Thus, the present descriptive retrospective analysis of the CRYSTAL trial investigated GHS/QoL and the individual dimensions of interest in mCRC in patients with RAS wt mCRC, which expands on the earlier CRYSTAL report 11 that assessed GHS/QoL in the KRAS wt population of the CRYSTAL study. We investigated these parameters within cetuximab's labeled indication (ie, patients with RAS wt mCRC) in many countries. QoL of Patients With RAS wt mCRC
Patients and Methods

Study Design and Patients
The study design, treatment parameters, eligibility criteria, and RAS ascertainment techniques for the phase III CRYSTAL trial have been previously reported. 1, 2, 13 In brief, patients with mCRC receiving first-line treatment were randomized to receive either cetuximab plus FOLFIRI or FOLFIRI alone. Treatment was continued until disease progression, symptomatic deterioration, or unacceptable toxicity. PFS by independent review was the primary endpoint of the CRYSTAL study.
QoL Assessments
Patient QoL was a secondary objective in the CRYSTAL study. The QoL was investigated using the European Organisation for Research and Treatment of Cancer QoL questionnaire core-30 (EORTC QLQ-C30).
14,15 EORTC QLQ-C30 scores are derived from 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 3 symptom scales (fatigue, nausea and vomiting, and pain), 6 symptom single-item scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and 1 GHS/QoL scale. The scale scores range from 0 to 100 after linear transformation. Higher scores for the functioning and GHS/QoL scales indicate greater levels of functioning and better QoL, respectively. In contrast, higher symptom scale scores indicate increased symptoms. Thus, a fully healthy individual would theoretically report functioning and GHS/QoL scale scores of 100 and symptom scale scores of 0. The QoL assessments were performed at baseline, after every 8 weeks of treatment, and at the final tumor assessment. Patients with 
Statistical Analysis
The QoL data were analyzed using descriptive statistics for the multi-item scales and single-item measures for each treatment group at each of the assessment points. In addition, an analysis of variance (ANOVA) model was fitted that included terms for age (< 65 or ! 65 years), gender (male or female), Eastern Cooperative Oncology Group performance status (ECOG PS), number of involved disease sites (1 or ! 2), and liver metastases (yes or no), and a treatment by time interaction. The least squares mean estimates for the time by treatment interaction and the difference in the least squares mean and associated standard errors were obtained from the ANOVA model. Subsequently, the difference between the 2 treatment groups was tested at each assessment point using t tests obtained from the multivariate model. Plots of the least squares mean by treatment group and the difference in the least squares mean and confidence interval (CI) over time were generated for the multi-item scales. Statistical outputs describing the time until the worsening of ECOG PS during the study were calculated using Kaplan-Meier estimates. These were descriptive analyses and were limited by the small number of patients. Accordingly, the data should be interpreted with appropriate caution (see the discussion section for further details).
Results
Of the 367 CRYSTAL study patients with RAS wt tumors, 13 351
were evaluable for QoL (Figure 1 ). The proportion of evaluable questionnaires was 79.7% and 76.3% in the cetuximab plus FOLFIRI and FOLFIRI arms, respectively. More than 90% of the missing questionnaires were attributable to non-QoL reasons (eg, patient believed it was inconvenient or required too much time). Also, patient compliance with EORTC QLQ-C30 questionnaire completion deteriorated over time.
The baseline characteristics were comparable between the treatment arms, with the exception that the ECOG PS favored the FOLFIRI group and more patients in the FOLFIRI arm had > 2 involved sites ( Table 1) .
The GHS/QoL during the study was similar between the treatment arms, although the analysis was complicated by the large decrease in the number of evaluable patients in the FOLFIRI arm between weeks 32 and 40 (Table 2; Figure 2 ). The GHS/QoL was comparable even with the addition of cetuximab to FOLFIRI early during treatment, when skin reactions would be anticipated to elicit the largest influence on QoL. 16 The changes in GHS/QoL and social functioning from baseline to week 8 were similar among the cetuximab-treated patients who experienced no early skin reactions, those who experienced grade 1 early skin reactions, and those who experienced grade 2 or 3 early skin reactions (Table 3) . Furthermore, physical functioning, fatigue, nausea and vomiting, and pain were similar between the cetuximab plus FOLFIRI and FOLFIRI groups (Table 2; Figure 3 ). Other individual dimensions of interest in mCRC (eg, social functioning, appetite loss, constipation, diarrhea, and functional difficulties) were also comparable between the 2 treatment arms (data not shown).
Finally, we assessed whether the time to the worsening of ECOG PS differed between the 2 treatment groups because this might serve as an additional surrogate for differences in patient QoL. Approximately one third of the patients receiving cetuximab plus FOLFIRI or FOLFIRI alone experienced documented worsening of the ECOG PS. The patients in the 2 treatment arms had a similar time to the worsening of ECOG PS, consistent with our other observations suggesting comparable QoL between RAS wt CRYSTAL study patients treated with cetuximab plus FOLFIRI and those treated with FOLFIRI ( Figure 4 ).
Discussion
We previously reported that the addition of cetuximab to FOL-FIRI improved PFS, OS, and ORR without negatively influencing QoL in CRYSTAL study patients with KRAS wt mCRC. 11 The results from the present exploratory and descriptive retrospective analysis of the RAS wt population of CRYSTAL-the labeled indication for cetuximab in many countries (rather than KRAS wt)-suggest that adding cetuximab to FOLFIRI does not negatively affect patient QoL. These findings are consistent with the QoL observations from the KRAS and RAS wt populations of the phase III PRIME trial [17] [18] [19] [20] [21] [22] [23] and the QoL findings from the KRAS wt population of the Cancer and Leukemia Group B/Southwestern Oncology Group 80405 trial. 24 In the latter trial, overall QoL was comparable between the cetuximab-and bevacizumab-containing treatment arms, although the effect of dermatologic conditions on QoL favored the bevacizumab plus FOLFIRI arm. 
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One notable observation from the present analysis is that GHS/QoL and social functioning did not differ between the 2 treatment arms early during treatment, the point at which skin reactions would be anticipated to elicit the largest influence on QoL. 16 The changes in GHS/ QoL and social functioning from baseline to week 8 were similar, irrespective of whether patients experienced early skin reactions. In addition to assaying overall GHS/QoL, we report the individual dimension data, some of which is highly pertinent to mCRC (eg, social functioning, fatigue, nausea and vomiting, pain, appetite loss, constipation, diarrhea, and functional difficulties) and an analysis of the time until the worsening of ECOG PS. These further data are consistent with our overall conclusion that the addition of cetuximab to FOLFIRI did not negatively affect the QoL of the RAS wt CRYSTAL study patients.
Our study was limited by its descriptive, exploratory, and retrospective nature and the low patient numbers and low questionnaire completion adherence at later assessment points. Our study was not adequately powered to robustly assess differences between the 2 treatment arms, in particular, at later points when the number of evaluable patients was relatively small. Patient compliance with EORTC QLQ-C30 QoL completion deteriorated over time. We believe that the large reduction in the number of evaluable patients between weeks 32 and 40 in the FOLFIRI arm might be attributable to the inability of patients with poor health status to complete questionnaires, thereby potentially confounding the interpretation of the data collected at later assessment points. Furthermore, we could not exclude the possibility that certain imbalances in baseline demographic and clinical characteristics (eg, ECOG PS favoring the FOLFIRI arm) might have influenced our findings. Another inherent limitation of our study was that the data were reliant on subjective and patient-reported outcomes rather than objectively measured parameters. Accordingly, these data should be viewed as hypothesis-generating.
Conclusion
The findings of the present descriptive retrospective analysis suggest that adding cetuximab to first-line FOLFIRI improves PFS, OS, and ORR without negatively affecting the QoL of CRYSTAL study patients with RAS wt mCRC. These data are consistent with our previous results from the KRAS wt population of the CRYSTAL study 11 and reinforce the notion that the addition of cetuximab to FOLFIRI extends patient survival without compromising QoL.
Clinical Practice Points
Data from the present exploratory and descriptive retrospective analysis suggest that the addition of cetuximab to first-line FOLFIRI improves survival without negatively affecting QoL for patients with RAS wt mCRC. These observations are broadly consistent with previous clinical evidence.
Figure 3 Continued
Physical functioning, fatigue, nausea and vomiting, and pain were similar between the cetuximab plus FOLFIRI and FOLFIRI groups. The plotted values correspond to the least squares mean values calculated for the indicated points. Higher scores for functioning and GHS/QoL scales indicate greater levels of functioning and better QoL, respectively. Higher symptom scale scores indicate increased symptoms. Abbreviations: FOLFIRI ¼ 5-fluorouracil, leucovorin, irinotecan; GHS ¼ global health status; QoL ¼ quality of life; wt ¼ wild type; n ¼ number of patients with available scores and no missing covariates.
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The findings from the present study on future clinical practice provide empirical confirmation that cetuximab can be used in conjunction with FOLFIRI to extend the survival of patients with mCRC without compromising their QoL.
